Digestive Health

Three-year QUASAR data show guselkumab keeps most ulcerative colitis patients in remission, with strong healing rates and no new safety issues.

Duvakitug TL1A antibody sustains remission and endoscopic response for 44 weeks in ulcerative colitis and Crohn disease, supporting phase 3 momentum.

The approval includes a single and once monthly maintenance injection compared with 2 100 mg/1 mL injections.

Less than 1 in 3 patients can very or extremely accurately predict when they will experience symptoms on a given day.

Among patients with cirrhosis receiving diuretic therapy, researchers explore the association between SGLT-2 inhibitors and the risk of serious liver outcomes.

In the researchers’ exploration of post-ICU nutritional care, they detailed the clinical pharmacist’s role and provided insights into how this role may evolve in the future.

In the study, the composition of the gut microbiome could also be affected by food insecurity, a known social determinant of health.

The review explored the “emerging” term gut-skin axis and aimed to decipher the bidirectional signaling of the skin and gastrointestinal tract during homeostatic and disease states.

Social media platforms provide an opportunity for pharmacists to create accurate content on inflammatory bowel disease for younger patients.

Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.

Pharmacists can substitute ustekinumab with the biosimilar at the pharmacy level, depending on their state laws.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.

Researchers investigated the health benefits, utilization, harms, and costs associated with the use of alternative methods for colorectal cancer screening in Australia.

Exploring data from the past 20 years, researchers investigated the end-organ complications from alcohol in adolescents and young adults.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

Help your patients overcome tummy troubles with trusted OTC products that relieve bloating, heartburn, and more, promoting smooth and happy digestion.

Patients who achieved clinical remission at 1 year in VIVID-1 maintain clinical remission at 92.9% at 2 years with the Crohn Disease Activity Index.

Sarah Gray, PharmD, GAICD, discussed her experience as a pharmacist who added nutrition counseling to her clinical expertise.

Sarah Gray, PharmD, GAICD, known as the Nutrition Pharmacist, joined Drug Topics to discuss her experience with patients looking to begin healthier lifestyles at the start of a new year.

Researchers performed a systematic literature review of the efficacy of amitriptyline for treating patients with irritable bowel syndrome.

Researchers conducted a literature research review to further understand the current evidence regarding diagnosis and treatment for peptic ulcer disease.

US News & World Report nutrition experts detailed the best types of diets for maintaining patient health in 2025.

Check out this list of our top 5 most read digestive health stories from the year 2024.

Researchers explored the impacts of natural bioactive compounds for the treatment of acute pancreatitis.